Soligenix Inc. is in an enviable position of being the beneficiary of positive interim data from its two late-stage trials. And, if the topline data expected in the next 6-9 months can confirm interim analyses, Soligenix may extend at least two significant development catalysts that can potentially change the company from a late-stage drug developer […]
